14/02/2016 01:38:00 Cookie Policy +44 (0) 207 0700 961 Free Membership Login

You’ve just added your first Follow! This is a brand new feature that will be at the core of several new tools and personalized information feeds that are coming soon.

You can see your current Follow list as a Monitor list here.

Please continue to add stocks to your Follow list so that when the new tools and feeds roll out, you’ll immediately get to make use of them! We will alert early adopters of the Follow list to these new features first.

Allergy Therapeutics Share Chat (AGY)

Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 26.00p 25.75p 26.25p 26.00p 26.00p 26.00p 5,000 07:53:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.2 0.7 0.0 1,300.0 152.58

Allergy Therapeutics Share Discussion Threads

Showing 3176 to 3200 of 3200 messages
Chat Pages: 128  127  126  125  124  123  122  121  120  119  118  117  Older
DateSubjectAuthorDiscuss
05/2/2016
13:49
Celeritas - another good find. I reckon that there is a bigger buy still to show here. Markets are not conducive!
jimmyloser
05/2/2016
12:35
Grass Pollen Allergy Market to Nearly Triple by 2020 Globally! htTp://www.medgadget.com/2016/02/grass-pollen-allergy-market-to-nearly-triple-by-2020-globally.html
celeritas
01/2/2016
12:22
Offering comfortably above 27p if you wish to sell.
jimmyloser
01/2/2016
12:02
Don't know how I missed this. Stick http at the front. ://www.proactiveinvestors.co.uk/companies/stocktube/4547/allergy-therapeutics-boss-says-the-firm-is-outperforming-its-competitors-4547.html Note he points out an adverse currency move in 2015 from 127 to 139, some 9.4% Since the end of November it's been a lot better with the pound weakening. Currently circa 131, much healthier. Currently only 3% above 2015. Guidance was inline with the currency headwinds which have now dissipated somewhat.
celeritas
29/1/2016
16:05
Stock is very tight now, only 10k up for sale online.
celeritas
29/1/2016
15:42
That 50k at 26.75 is a buy
celeritas
29/1/2016
15:04
I should think so! With an update on the USA/Canadian trials imminent too.
jimmyloser
21/1/2016
11:00
Allergy Therapeutics Financial Director Ian Postlethwaite will be presenting to investors from 6pm on 28th January at the Proactive One2One Forum in Mayfair. To register to attend, please click here: http://tinyurl.com/gtt2eqy
aim_trader
13/1/2016
09:37
In-line, could really have done with ahead. PHTM put out a great update looking likely to be materially ahead with Japan 90% higher than the previous year. It's up a tad on what should have been a huge uplift. The mkt just doesn't seem to want to know lately.
celeritas
13/1/2016
07:42
May halt there ent drift although I want to top-up in Feb so any short-term pull back is welcome from my perspective.
audigger
13/1/2016
07:06
That is very encouraging news this morning and with the euro having strengthened considerably since that period end, it puts a little wind back in our sails. impo/dyor
jimmyloser
24/12/2015
08:07
Have a good one folks and many big returns in 2016 (thou a bit longer will be needed for the fruits of AGY to be fully realised...)!
audigger
23/12/2015
18:57
About time Jimmy. About time. Here's hoping but in mean time Merry Christmas and Happy and prosperous New Year to you
qackers
23/12/2015
17:31
Merry Christmas and a Happy New Year to all regular AGY contributors. Jimmy L. PS: Probably have to change my name next year!
jimmyloser
18/12/2015
12:09
nice find guys !
treeshake
18/12/2015
10:22
No Problem. Looking good. Hard to find a company of this size with a realistic possibility of significant technology break through in a major market backed by a solid business.
qackers
18/12/2015
10:18
Was just about to post that Quackers, you beat me to it. Decent news for agy.
celeritas
18/12/2015
10:08
http://www.proactiveinvestors.co.uk/companies/news/120585/allergy-therapeutics-could-gain-from-rival-s-problems-says-panmure-120585.html?utm_source=Sign-Up.to&utm_medium=email&utm_campaign=7163-345237-Proactivity+-+17%2F12%2F2015 Allergy Therapeutics could gain from rival's problems, says Panmure 11:30 17 Dec 2015 French group Stallergenes had to temporarily close its Antony manufacturing plant Allergy Therapeutics could gain from rival's problems, says Panmure Allergy Therapeutics is a hay fever vaccine specialist. Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) could get a short-term boost following a competitors manufacturing suspension, according to house broker Panmure Gordon. French group Stallergenes had to temporarily close its Antony manufacturing plant earlier this month due to IT problems. The company could be forced to recall all products released from the site since August, benefitting its competitors, Panmure said. Though Allergy focuses mainly on injection treatments, the company has Oralvac, a product that falls into the oral market. Oralvac accounted for around 15% of Allergy’s revenues last year, and, as a result, the firm could benefit from the temporary closure. Panmure said: “We consider this additional dynamic might provide some (temporary) tailwind effect in certain product categories.” It also noted that Allergy has been making market share gains in Europe despite flat trading conditions, and that this episode highlighted Allergy’s own “exemplary” compliance record. The broker repeated its ‘buy’ recommendation on the stock, with a target price of around 51p. Shares were broadly flat at 31p on Thursday. Share Jonathan Jones
qackers
16/12/2015
10:24
Sorry you might have seen this post in other discussion but anyway...Short TV update below from Manuel & Ian discussing placing, trading update and clinical progress. www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
oshy92
16/12/2015
10:22
Morning. Short TV update below from Manuel & Ian discussing placing, trading update and clinical progress. www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
oshy92
11/12/2015
14:18
Pollinex Quattro will be huge in the States, massive mkt to aim at. It's already doing well in Europe, I see no reason why it won't do the same in the States. This is well worth reading again, 93p valuation. htTp://www.hardmanandco.com/system/files/research_papers/Allergy%20Therapeutics%20Initiation%2021.10.15b.pdf
celeritas
11/12/2015
13:15
Thanks Cel. Interesting interview and a good insight in to how they plan to position this with FDA.
audigger
11/12/2015
10:43
htTp://www.directorstalkinterviews.com/allergy-therapeutics-plc-tim-higenbottam-rd-director-on-g204-phase-2-study/412686588
celeritas
07/12/2015
08:09
FINGERS CROSSED, WE ARE ON OUR WAY! Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") US Phase II study for GrassMATAMPL initiated Headline data expected Q2 2016; US clinical development plans on track Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces enrolment of the first ten US patients in the Company's GrassMATAMPL ("GMM") 204 phase II study (G204). G204 is a double-blind, placebo-controlled cumulative dose selection study for grass allergic rhinitis, which follows the successful completion of the GMM102 (G102) safety study, which demonstrated safety of two new doses of GMM and supports the further testing of efficacy in the current G204 study. The G204 phase II study has been agreed with the FDA, is expected to read out in the second quarter of 2016, and precedes the initiation of the pivotal phase III study for US approval. GMM is developed from Allergy Therapeutics' successfully marketed Pollinex Quattro Grass product, which has been available in Europe for a number of years treating circa 250,000 patients(1) , and is designed to provide a uniquely ultra-short course of injections to prevent seasonal grass allergy. Grass allergy occurs in up to 50% of the US population(2) of those suffering from seasonal allergic rhinitis/conjunctivitis, and is often poorly controlled by anti-leukotrienes and nasal corticosteroids. Manuel Llobet, CEO of Allergy Therapeutics, said: "The US clinical development programme for our ultra-short course, aluminium-free allergy vaccine for grass remains on track. We continue to expect to file for US approval at the end of 2018. The US allergy immunotherapy market has historically been serviced by subcutaneous rather than sublingual compounded vaccines. We are therefore confident that the availability of an FDA-approved subcutaneous vaccine, which we are striving to achieve, will facilitate a fast penetration and broad acceptance of the product among the prescriber base." References 1 Allergy Therapeutics Data 2 DataMonitor Epidemiology - Epidemiology Allergic Rhinitis -March 2011 For further information:
jimmyloser
03/12/2015
09:26
What on earth is this all about 1.75p spread - ridiculous! OR HAS THIS BEEN TIPPED SOMEWHERE ?
jimmyloser
Chat Pages: 128  127  126  125  124  123  122  121  120  119  118  117  Older


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20160214 01:38:00